Metastatic Malignant Neoplasm in the Brain Clinical Trial
Official title:
A Phase II Study of Ferumoxytol and Gadolinium Magnetic Resonance Imaging at 3T and 7T in Subjects With Primary or Metastatic Brain Tumors Either Before or After Therapy
This phase II trial studies how well magnetic resonance imaging (MRI) using contrast imaging agent ferumoxytol works in comparison to standard imaging agent gadolinium in measuring tumors in patients undergoing treatment for brain tumors or other tumors that have spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose disease and find out how far the disease has spread. MRI scans use radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. The contrast imaging agent ferumoxytol consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It is highly visible on the MRI, and may help visualize the blood flow going through the tumor better than gadolinium can. Using a more sensitive and faster 7 Tesla (7T) magnet MRI in conjunction with a contrast imaging agent may provide a better way to measure tumors than the 3 Tesla (3T) magnet MRI in patients with brain tumors.
PRIMARY OBJECTIVES: I. To compare quantitative blood brain barrier permeability measurements (derived transfer coefficient [Ktrans]) of a standard gadolinium (Gd) MRI contrast agent at 3T and 7T using dynamic contrast enhancement (DCE) MRI. II. To compare dynamic susceptibility contrast (DSC) based perfusion measures at 3T and 7T. SECONDARY OBJECTIVES: I. To describe the blood brain barrier permeability to ferumoxytol (ferumoxytol non-stoichiometric magnetite) and to a standard gadolinium-based MRI contrast agent using signal intensity changes as described above. II. To describe cerebral blood volume (CBV) measurements obtained using a standard gadolinium MRI contrast agent and ferumoxytol. III. To evaluate tumor microvascularity on susceptibility-weighted images (SWI). IV. To describe the microscopic distribution of ferumoxytol particles in tissue removed from subjects undergoing surgery. OUTLINE: Patients are assigned to 3T or 7T magnet within the subgroups. Patients receive gadolinium intravenously (IV) on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2. Patients undergo anatomical MRI sequences with 3T or 7T at baseline and on days 1-3. Patients also undergo DSC MRI and DCE MRI on days 1-2. Day 1 and day 2 imaging sessions may be separated by up to 7 days. After completion of study, patients are followed up at approximately 4-6 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04062305 -
nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex
|
N/A | |
| Recruiting |
NCT05388877 -
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT03071913 -
Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
|
||
| Active, not recruiting |
NCT02595905 -
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT03270059 -
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
|
Phase 2 | |
| Terminated |
NCT00096265 -
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
| Recruiting |
NCT04250545 -
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05341349 -
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT04114981 -
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
|
Phase 3 | |
| Recruiting |
NCT03741673 -
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
|
Phase 3 | |
| Completed |
NCT03680144 -
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
|
N/A | |
| Completed |
NCT02167204 -
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
|
N/A | |
| Recruiting |
NCT03750227 -
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
|
Phase 3 | |
| Recruiting |
NCT03418961 -
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02993146 -
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
|
Phase 1 | |
| Not yet recruiting |
NCT06328686 -
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
|
Early Phase 1 | |
| Active, not recruiting |
NCT02589522 -
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
|
Phase 1 | |
| Recruiting |
NCT04804644 -
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
|
Phase 3 | |
| Withdrawn |
NCT03868423 -
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
|
Phase 2 |